Actively Recruiting
Comparing Brivudine and Famciclovir for Treating Herpes Zoster A Multicenter Randomized Trial
Led by Peking University Third Hospital · Updated on 2026-01-02
140
Participants Needed
4
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of two antiviral drugs, Brivudine and Famciclovir, in treating adults with acute herpes zoster. This multicenter, randomized controlled trial aims to compare how well these medications reduce pain using the Numeric Pain Rating Scale NPRS at various points, with the primary focus on pain at Day 30. The study also looks at healing time of skin lesions, incidence of Postherpetic Neuralgia PHN, and safety outcomes in participants. Participants are randomly assigned to receive either Brivudine at a dose of 125 mg once daily for 7 days or Famciclovir dosed orally based on kidney function for the same duration. The treatment period lasts one week, with follow-up visits scheduled on Day 3, Day 7, Day 14, Day 30, and Day 90 to monitor effects and collect data on pain levels, lesion healing, and any adverse events. During the study, participants undergo pain assessments using the NPRS at multiple timepoints and evaluations of their skin lesions for healing progress. Researchers also track the development of Postherpetic Neuralgia up to Day 90 and monitor for any side effects or serious adverse events from baseline through Day 30. This comprehensive monitoring aims to ensure participant safety and gather detailed information on the treatments impact over a three-month period.
CONDITIONS
Brief Title
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
Research Team
J
Jin-Zhu Guo, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here